

Bern, January 2026

### Swiss Cancer Institute / Astellas & AstraZeneca Translational GU Oncology Research Award

The Swiss Cancer Institute and Astellas & AstraZeneca are pleased to announce an award for 10'000 CHF aimed at supporting ongoing translational GU oncology research. Hence the awarded sum is to be used for on-going and future research within the respective research group or project. The award is sponsored 50% by AstraZeneca and Astellas each.

### Eligible Projects

- Projects should be translational in nature. They should be aimed at translating basic research discoveries into the clinic. Possible projects could include, but are not limited to:
  - Development of novel treatments for GU cancers focused on small molecules, biologics, or radioligand therapies
  - Development of diagnostic modalities for GU cancers
  - Development of novel prevention strategies for GU cancers
- Approaches can include preclinical, animal, human tissue, and/or human studies
- Purely basic research projects are out of scope.
- Must be conducted in Switzerland but can be part of larger collaborative projects. In the case of the latter, the submitted project should be a substantial part of such an overarching project and focus on a specific aspect. Only costs that are still occurring can be covered by the award.

### Eligible Applicants

Applicants must have a primary place of work in Switzerland and can include graduate or postgraduate researchers or physician-scientists.

### Application Process and Timelines

To be considered for the award, please submit the abstract with no more than 300 words and your CV for this meeting by April 27, 2026 to [events@swisscancerinstitute.ch](mailto:events@swisscancerinstitute.ch). Only complete submissions can be considered. Briefly, the application must:

- Be written in English language.
- The abstract of not more than 300 words should include a project title, the rationale, aim of the project, and how this research will be translated into the clinic.

### Jury

The Scientific Committee of the Swiss Cancer Institute Translational Urogenital Cancer Network Meeting 2026 will review all submitted projects and select those eligible for the oral presentation during the Network Meeting on 18/19 June 2026.

After all presentations have been delivered, the committee will decide on the winning project.

### Criteria for Project Evaluation

Project proposals will only be evaluated if they are deemed to be eligible and feasible according to the project scope defined above. Evaluation will be based on the presentation/abstract and on the following criteria:

- Estimated impact on GU cancer outcomes
- Translatability of the project
- Novelty of the project
- Oral presentation skills: ability to answer questions and defend the project



### Notification and Award

The award winner will be announced at the Swiss Cancer Institute Translational Urogenital Cancer Network Meeting 2026 on 19 June 2026.

### Contact Details

Swiss Cancer Institute  
Effingerstrasse 33  
3008 Bern  
Tel +41 31 389 91 91  
E-Mail: [events@swisscancerinstitute.ch](mailto:events@swisscancerinstitute.ch)